A carregar...
The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease
Crizanlizumab is a monoclonal antibody that binds to P-selectin. On October 28, 2020, a conditional marketing authorization valid through the European Union (EU) was issued for crizanlizumab for the prevention of recurrent vaso-occlusive crises (VOCs) in patients with sickle cell disease aged 16 yea...
Na minha lista:
| Publicado no: | Hemasphere |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Lippincott Williams & Wilkins
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8240778/ https://ncbi.nlm.nih.gov/pubmed/34235401 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HS9.0000000000000604 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|